BREAKING NEWS
Cloud Server Hosting For Online Businesses
Inexpensive SEO Services
Benefits of Wanting to play Free Online Slot machines
Fenofibrate/simvastatin

Summary

Fenofibrate/simvastatin, sold under the brand name Cholib, is a fixed-dose combination medication used to treat abnormal blood lipid levels when used in combination with a low-fat diet and exercise.[1] It contains fenofibrate and simvastatin.[1]

Fenofibrate/simvastatin
Combination of
FenofibrateFibrate
SimvastatinStatin
Clinical data
Trade namesCholib
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Identifiers
CAS Number
  • 2447635-10-9
KEGG
  • D10857

It was approved for use in the European Union in August 2013.[1]

Medical uses edit

Fenofibrate/simvastatin is indicated as adjunctive therapy to diet and exercise in high cardiovascular risk adults with mixed dyslipidemia to reduce triglycerides and increase HDL C levels when LDL C levels are adequately controlled with the corresponding dose of simvastatin monotherapy.[1]

Adverse effects edit

References edit

  1. ^ a b c d e "Cholib EPAR". European Medicines Agency (EMA). 5 March 2020. Retrieved 5 March 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

Further reading edit

  • Filippatos TD, Elisaf MS (2015). "Safety considerations with fenofibrate/simvastatin combination". Expert Opin Drug Saf. 14 (9): 1481–93. doi:10.1517/14740338.2015.1056778. PMID 26134595. S2CID 207488283.
  • Tarantino N, Santoro F, De Gennaro L, et al. (2017). "Fenofibrate/simvastatin fixed-dose combination in the treatment of mixed dyslipidemia: safety, efficacy, and place in therapy". Vasc Health Risk Manag. 13: 29–41. doi:10.2147/VHRM.S95044. PMC 5317328. PMID 28243111.

External links edit

  • "Fenofibrate". Drug Information Portal. U.S. National Library of Medicine.
  • "Simvastatin". Drug Information Portal. U.S. National Library of Medicine.